{"component": "definition", "props": {"groups": [{"snippet": "means First Indication and Second Indication.", "size": 8, "snippet_links": [{"key": "first-indication", "type": "clause", "offset": [6, 22]}, {"key": "second-indication", "type": "clause", "offset": [27, 44]}], "samples": [{"hash": "kEChXeh7teY", "uri": "/contracts/kEChXeh7teY#indications", "label": "License Agreement (Crinetics Pharmaceuticals, Inc.)", "score": 33.3586578369, "published": true}, {"hash": "aAtzJP9vIo0", "uri": "https://ir.crinetics.com/static-files/962f9613-7cd4-44f5-b104-074d3dda6739", "label": "ir.crinetics.com", "score": 11.4572210312, "published": false}], "hash": "0580728455fd95fc02db190590a4e1a5", "id": 1}, {"snippet": "means indications for the human and/or veterinary uses of the Products.", "size": 6, "snippet_links": [{"key": "the-human", "type": "clause", "offset": [22, 31]}, {"key": "the-products", "type": "clause", "offset": [58, 70]}], "samples": [{"hash": "kHuEmKKNSd5", "uri": "/contracts/kHuEmKKNSd5#indications", "label": "License Agreement (Melinta Therapeutics, Inc. /New/)", "score": 29.4325809479, "published": true}, {"hash": "bU94zLdq88u", "uri": "/contracts/bU94zLdq88u#indications", "label": "License Agreement (Melinta Therapeutics, Inc. /New/)", "score": 29.1971244812, "published": true}, {"hash": "cgVgZu4xClz", "uri": "/contracts/cgVgZu4xClz#indications", "label": "Patent Prosecution Control Agreement (Rib-X Pharmaceuticals, Inc.)", "score": 23.2806301117, "published": true}], "hash": "88868a632c82f8e9077369d2db6b01d5", "id": 2}, {"snippet": "means a disease classification as defined within the \u201cInternational Statistical Classification of Diseases and Related Health Problems\u201d as published on the date hereof by the World Health Organization (e.g. F10 Mental and Behavioral Disorders due to the use of Alcohol is a distinct indication from F14 Mental and Behavioral Disorders due to the use of Cocaine).", "size": 4, "snippet_links": [{"key": "health-problems", "type": "clause", "offset": [119, 134]}, {"key": "date-hereof", "type": "clause", "offset": [156, 167]}, {"key": "the-world-health-organization", "type": "clause", "offset": [171, 200]}, {"key": "mental-and-behavioral-disorders", "type": "definition", "offset": [211, 242]}, {"key": "the-use-of-alcohol", "type": "clause", "offset": [250, 268]}, {"key": "distinct-indication", "type": "definition", "offset": [274, 293]}], "samples": [{"hash": "1mqWkV876Xe", "uri": "/contracts/1mqWkV876Xe#indications", "label": "License Agreement (Indivior PLC)", "score": 32.388092041, "published": true}, {"hash": "d4wj7lDwfls", "uri": "/contracts/d4wj7lDwfls#indications", "label": "License Agreement (Indivior PLC)", "score": 32.1854896545, "published": true}, {"hash": "3h9UZnRUFDy", "uri": "/contracts/3h9UZnRUFDy#indications", "label": "License Agreement (Addex Therapeutics Ltd.)", "score": 30.9575634003, "published": true}], "hash": "4be98fc954f2b7acd74a98c3bf8aabfa", "id": 3}, {"snippet": "means the Initial Indications and all other indications within the Field.", "size": 4, "snippet_links": [{"key": "initial-indications", "type": "clause", "offset": [10, 29]}, {"key": "other-indications", "type": "definition", "offset": [38, 55]}, {"key": "the-field", "type": "clause", "offset": [63, 72]}], "samples": [{"hash": "hORQbhqv4YQ", "uri": "/contracts/hORQbhqv4YQ#indications", "label": "License and Collaboration Agreement (Spectrum Pharmaceuticals Inc)", "score": 22.1854896545, "published": true}, {"hash": "GSSAIAx4hz", "uri": "/contracts/GSSAIAx4hz#indications", "label": "License and Collaboration Agreement (Spectrum Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "4sWzML2dJx1", "uri": "/contracts/4sWzML2dJx1#indications", "label": "License and Collaboration Agreement (Spectrum Pharmaceuticals Inc)", "score": 18.0, "published": true}], "hash": "7f9ad11864ff7e1a8813b5fe38647269", "id": 4}, {"snippet": "means those indications listed on Exhibit B and any other indications to be agreed upon hereafter between FG and Astellas, each of which shall be referred to as an Indication.", "size": 4, "snippet_links": [{"key": "exhibit-b", "type": "definition", "offset": [34, 43]}, {"key": "other-indications", "type": "definition", "offset": [52, 69]}], "samples": [{"hash": "ZX37QHVGxN", "uri": "/contracts/ZX37QHVGxN#indications", "label": "Collaboration Agreement (Fibrogen Inc)", "score": 25.7282676697, "published": true}, {"hash": "8km8A7VFUul", "uri": "https://www.sec.gov/Archives/edgar/data/921299/000156459020051315/fgen-ex101_102.htm", "label": "Fibrogen Inc", "score": 15.8446273804, "published": false}, {"hash": "28xTiQJwA10", "uri": "https://www.sec.gov/Archives/edgar/data/921299/000156459017022738/fgen-ex109_208.htm", "label": "Fibrogen Inc", "score": 12.8521556854, "published": false}], "hash": "1f056dfc7a3942e7f231722676e13795", "id": 5}, {"snippet": "means the ophthalmic, sinusitis and otic indications.", "size": 4, "snippet_links": [], "samples": [{"hash": "3Wa90hLnrHn", "uri": "/contracts/3Wa90hLnrHn#indications", "label": "License and Supply Agreement (Ruthigen, Inc.)", "score": 24.7891845703, "published": true}, {"hash": "cFzDiXIxCSg", "uri": "/contracts/cFzDiXIxCSg#indications", "label": "License and Supply Agreement (Oculus Innovative Sciences, Inc.)", "score": 24.7289524078, "published": true}, {"hash": "d56VMsmYXPU", "uri": "/contracts/d56VMsmYXPU#indications", "label": "License and Supply Agreement (Ruthigen, Inc.)", "score": 24.6002731323, "published": true}], "hash": "1f09971dad3cd1da43b5402d44f3eaf2", "id": 6}, {"snippet": "means any disease, illness, mental condition or other malady of humans or animals. INDICATION shall specifically include treatment of amyotrophic lateral sclerosis, [* * *].", "size": 4, "snippet_links": [{"key": "mental-condition", "type": "definition", "offset": [28, 44]}, {"key": "treatment-of", "type": "definition", "offset": [121, 133]}, {"key": "amyotrophic-lateral-sclerosis", "type": "definition", "offset": [134, 163]}], "samples": [{"hash": "8bXn83vAd3E", "uri": "/contracts/8bXn83vAd3E#indications", "label": "Als Biopharma Agreement (Biohaven Research Ltd.)", "score": 33.6050643921, "published": true}, {"hash": "6fHUshNt2TP", "uri": "/contracts/6fHUshNt2TP#indications", "label": "Als Biopharma Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 28.3100624084, "published": true}, {"hash": "ldqyyVi7TI0", "uri": "/contracts/ldqyyVi7TI0#indications", "label": "Als Biopharma Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 28.2635173798, "published": true}], "hash": "54dccc38be220d477cdbfa5c80db41e6", "id": 7}, {"snippet": "means any and all insulin resistant diabetes claimed in the LICENSED PATENT RIGHTS which are [REDACTED] and (vi) other indications which both parties agree from time to time to be included within the scope of the claims of the LICENSED PATENT RIGHTS by good faith scientific and legal judgment.", "size": 4, "snippet_links": [{"key": "licensed-patent-rights", "type": "definition", "offset": [60, 82]}, {"key": "other-indications", "type": "definition", "offset": [113, 130]}, {"key": "both-parties-agree", "type": "clause", "offset": [137, 155]}, {"key": "from-time-to-time", "type": "clause", "offset": [156, 173]}, {"key": "claims-of", "type": "clause", "offset": [213, 222]}, {"key": "good-faith", "type": "clause", "offset": [253, 263]}], "samples": [{"hash": "eVPtfaHBq3L", "uri": "/contracts/eVPtfaHBq3L#indications", "label": "License Agreement (Insmed Inc)", "score": 21.0, "published": true}, {"hash": "4USod2P1BC9", "uri": "/contracts/4USod2P1BC9#indications", "label": "License Agreement (Insmed Inc)", "score": 21.0, "published": true}, {"hash": "3PyXY9rd5YI", "uri": "/contracts/3PyXY9rd5YI#indications", "label": "License Agreement (Insmed Inc)", "score": 21.0, "published": true}], "hash": "e8083b777dc98c20c48c087eb5cb8b15", "id": 8}, {"snippet": "means any indication bearing a distinct reference number under the list of diseases officially published by the World Health Organization (WIN)) or list of disorders published in the American Psychiatric Association\u2019s Diagnostic and Statistical Manual of Mental Disorders (DSM 5, or above) or such successor organizations that are in effect at the relevant time during the term of this Agreement.", "size": 3, "snippet_links": [{"key": "reference-number", "type": "definition", "offset": [40, 56]}, {"key": "officially-published", "type": "definition", "offset": [84, 104]}, {"key": "the-world-health-organization", "type": "clause", "offset": [108, 137]}, {"key": "diagnostic-and-statistical-manual-of-mental-disorders", "type": "clause", "offset": [218, 271]}, {"key": "successor-organizations", "type": "clause", "offset": [298, 321]}, {"key": "in-effect", "type": "definition", "offset": [331, 340]}, {"key": "relevant-time", "type": "clause", "offset": [348, 361]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [362, 395]}], "samples": [{"hash": "dX0gTJ6MEKF", "uri": "/contracts/dX0gTJ6MEKF#indications", "label": "Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 28.3100624084, "published": true}, {"hash": "11FAvnqLhZb", "uri": "/contracts/11FAvnqLhZb#indications", "label": "Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 28.2635173798, "published": true}, {"hash": "gBT8EVHa1hx", "uri": "/contracts/gBT8EVHa1hx#indications", "label": "Exclusive Patent License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)", "score": 28.1211490631, "published": true}], "hash": "2c1fa15b5586121fcce5ba813ed12dff", "id": 9}, {"snippet": "means any indication bearing a distinct reference number under the list of diseases officially published by the World Health Organization (WHO) or list of disorders published in the American Psychiatric Association\u2019s Diagnostic and Statistical Manual of Mental Disorders (DSM 5, or above) or such successor organizations that are in effect at the relevant time during the term of this Agreement.", "size": 3, "snippet_links": [{"key": "reference-number", "type": "definition", "offset": [40, 56]}, {"key": "officially-published", "type": "definition", "offset": [84, 104]}, {"key": "the-world-health-organization", "type": "clause", "offset": [108, 137]}, {"key": "diagnostic-and-statistical-manual-of-mental-disorders", "type": "clause", "offset": [217, 270]}, {"key": "successor-organizations", "type": "clause", "offset": [297, 320]}, {"key": "in-effect", "type": "definition", "offset": [330, 339]}, {"key": "relevant-time", "type": "clause", "offset": [347, 360]}, {"key": "during-the-term-of-this-agreement", "type": "clause", "offset": [361, 394]}], "samples": [{"hash": "fxGmmW3ZLXp", "uri": "https://www.sec.gov/Archives/edgar/data/1689813/000104746917002826/a2231899zex-10_4.htm", "label": "Biohaven Pharmaceutical Holding Co Ltd.", "score": 12.3100614548, "published": false}, {"hash": "gEymLAk3owr", "uri": "https://www.sec.gov/Archives/edgar/data/1689813/000104746917002426/a2231694zex-10_4.htm", "label": "Biohaven Pharmaceutical Holding Co Ltd.", "score": 12.2635183334, "published": false}, {"hash": "jMwH691hBjS", "uri": "https://www.sec.gov/Archives/edgar/data/1689813/000091205717000031/filename9.htm", "label": "Biohaven Pharmaceutical Holding Co Ltd.", "score": 12.1211500168, "published": false}], "hash": "efd9a76bfaaf4515cb44e64866e781ec", "id": 10}], "next_curs": "ClgSUmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjQLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIUaW5kaWNhdGlvbnMjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means First Indication and Second Indication.", "size": 153, "title": "Indications", "id": "indications", "examples": ["<strong>Indications</strong> that a subcontractor is not performing a commercially useful function include, but are not limited to, labor shifting and equipment sharing or leasing arrangements with the prime contractor or a first tier subcontractor.", "<strong>Indications</strong> of deposits of more recent historic interest may be the exposure of dumps in landfill areas, abandoned campfire sites, and building foundations.", "The Parties shall cooperate in good faith in generating ideas and concepts for Additional <strong>Indications</strong> for Products.", "<strong>Indications</strong> from any redundant determining devices should be reported to the Parties for verification purposes.", "The Geographical <strong>Indications</strong> Sub-Committee is hereby established.", "In exercising such termination right, Licensee may terminate this Agreement in its entirety or, if desired, Licensee may specify in the written notice that this Agreement is terminating only with respect to one or more of the Licensed <strong>Indications</strong> within the Field.", "Following the exercise of a Commercial Option, Licensee will use commercially reasonable efforts to develop, commercialize, market, promote, and sell Licensed Products for each of the Licensed <strong>Indications</strong> within the Field.", "<strong>Indications</strong> of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.", "Notwithstanding the foregoing, BTC will advise the JDC of all Development and Commercialization of Remaining <strong>Indications</strong>.", "Furthermore, the Parties agree to conclude as soon as possible a bilateral Agreement on Geographical <strong>Indications</strong>."], "related": [["antipsychotic-medications", "Antipsychotic medications", "Antipsychotic medications"], ["biological-samples", "Biological Samples", "Biological Samples"], ["complex-product", "complex product", "complex product"], ["cannabis-product", "Cannabis product", "Cannabis product"], ["biological-product", "Biological product", "Biological product"]], "related_snippets": [], "updated": "2025-11-09T12:08:30+00:00"}, "json": true, "cursor": ""}}